Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis (MMNNIRP)

March 10, 2015 updated by: Hongyu Jie, The Third Affiliated Hospital of Southern Medical University
Neutrophils play a central role in innate immunity and are rapidly recruited to sites of infection and injury. Neutrophil apoptosis and necroptosis are essential for the inflammatory.This study is designed to investigate the cells and the molecular mechanisms of neutrophil necroptosis and apoptosis.

Study Overview

Status

Unknown

Conditions

Detailed Description

Necrosis has recently been demonstrated to be programmatic and energy comsuming, a process termed necroptosis.

In this project, the investigators aim to investigate the mechanisms and the effects ofneutrophil necroptosis and apoptosis: 1. to investigate the cells and the molecular mechanisms that induce neutrophil necroptosis or delay apoptosis, mainly focusing on the roles of HMGB-1,TNF-α and LPS, 2. to illustrate the effects of some molecules such as TLR, TNFR, RIP1/RIP3, Caspase8, ATP and ROS in the process of sigal transduction and membrane damage during necroptosis or apoptosis , 3. to identify the similarities and differences between traditional necrosis and necroptosis in the aspects of morphologigical changes and inflammatory cytokine release, 4. to find out the effects and mechanisms of neutrophil necroptosis or apoptosis in a rheumatoid arthritis mouse model and the therapeutic effect of blocking one or several pathways in the pathogenesis of rheumatoid arthritis.

This study will not only unravel the mechanisms of neutrophil necroptosis and apoptosis, elucidate its roles and significances in inflammation and infection, but also shed new light on anti-inflammatory and anti-infection therapy.

Study Type

Observational

Enrollment (Anticipated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510500
        • Recruiting
        • Third Affiliated Hospital of Southern Medical University
        • Contact:
        • Contact:
          • ewei Sun, doctor
          • Phone Number: +86 020-62784421
          • Email: ewsun@263.net
      • Guangzhou, Guangdong, China, 510500
        • Not yet recruiting
        • Third Affiliated Hospital of Southern Medical University
        • Contact:
        • Contact:
          • ewei Sun, doctor
          • Phone Number: +86 020-62784421
          • Email: ewsun@263.net

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Healthy Volunteers，age 18-65.

Description

Inclusion Criteria:

  • Healthy Volunteers
  • age 18-65.

Exclusion Criteria:

  • Don't agree with informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The apopotosis and necroptosis of Neutrophils
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Third Affiliated Hospital of Southern Medical University

Investigators

  • Study Director: ew Sun, doctor, Third Affiliated Hospital of Southern Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2015

Primary Completion (Anticipated)

September 1, 2015

Study Completion (Anticipated)

February 1, 2016

Study Registration Dates

First Submitted

March 5, 2015

First Submitted That Met QC Criteria

March 10, 2015

First Posted (Estimate)

March 11, 2015

Study Record Updates

Last Update Posted (Estimate)

March 11, 2015

Last Update Submitted That Met QC Criteria

March 10, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 201501004

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe